Gilead Sciences, Inc. vs Lucid Group Inc — how do they compare? Gilead Sciences, Inc. trades at $135.19 (market cap $168.35B), while Lucid Group Inc trades at $6.69 (market cap $2.64B). The key difference: Gilead Sciences, Inc. is far larger — about 63.8× Lucid Group Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| GILD | LCID | |
|---|---|---|
Market Cap | $168.35B | $2.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $24.77 |
52-Week Low | $110.56 | $4.62 |
Enterprise Value | $191.42B | $5.54B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →